Tags : Targeting

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting

Shots: Scenic to receive ~$375M that includes up front, milestones along with royalties on sales of therapies emerges from the collaboration and will receive additional target fees for the therapies selected by Genentech The collaboration allows the Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will leverage […]Read More

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected […]Read More

AbbVie Signs an Exclusive Research and Option to License Agreement

Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More

Merck Collaborates with Yumanity to Accelerate the Development of Two

Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience    Yumanity and […]Read More